Radiation associated coronary occlusion: Overlooked as trastuzumab-induced cardiomyopathy
暂无分享,去创建一个
Trastuzumab is an agent used for receptor-positive breast cancer. Up to a third of patients treated with trastuzumab might develop cardiomyopathy. Many patients with breast cancer have taken pre- or co-administration of mediastinal radiotherapy. Both of treatment modalities have toxic effects on myocardium. It may result with diagnostic confusion between radiation-induced CAD (riCAD) and trastuzumab cardiomyopathy in the case with dilated cardiomyopathy. TTE may offer clues of differential diagnosis.
[1] M. Guglin,et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. , 2009, Journal of cardiac failure.
[2] J. Cuzick,et al. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study , 2007, BMC Cancer.
[3] Aamer Chughtai,et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. , 2011, International journal of radiation oncology, biology, physics.